95 results about "HIV Antigens" patented technology

The present invention concerns methods and compositions for treatment of HIV infection in a subject. The compositions may comprise a targeting molecule against an HIV antigen, such as an anti-HIV antibody or antibody fragment. The anti-HIV antibody or fragment may be conjugated to a variety of cytotoxic agents, such as doxorubicin. In a preferred embodiment, the antibody or fragment is P4/D10. Other embodiments may concern methods of imaging, detection or diagnosis of HIV infection in a subject using an anti-HIV antibody or fragment conjugated to a diagnostic agent. In alternative embodiments, a bispecific antibody with at least one binding site for an HIV antigen and at least one binding site for a carrier molecule may be administered, optionally followed by a clearing agent, followed by administration of a carrier molecule conjugated to a therapeutic agent.

The invention provides immunogenic compositions which enhance beta-chemokine levels in a mammal. The immunogenic compositions contain an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. The HIV antigen can be a whole-killed HIV virus devoid of outer envelope protein gp120. Alternatively, the HIV antigen can be a whole-killed HIV virus, or a p24 antigen. Also provided are kits, the components of which, when combined, produce the immunogenic compositions of the invention. The invention also provides methods of making the immunogenic compositions, by combining an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. The invention further provides a method of immunizing a mammal, by enhancing beta-chemokine production in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. Also provided is a method of inhibiting AIDS, by enhancing beta-chemokine production in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant.

The invention relates to biology applied technology field, especially relates to a immune chromatography assay for quickly detecting the human immunologic deficiency disease (HIV) antibody and antigen. The assay comprises two independent test papers A and B and plastic case C for storing the test paper, wherein the test paper A is used for detecting the HIV antibody and the test paper B is used for detecting the HIV p24 antigen. The test paper A and test paper B are parallely encased in the plastic case to constitute the assay. On detecting, the detected sample is added on the sample pad of the test paler and the immunoreaction result is directly observed to perform detection. The assay is used for screening or clinical diagnosis of the HIV infection and at the same time the HIV antigen and antibody are detected, the simpler antibody detection can effectively reduce the window phase for detecting the HIV, with features of quick reaction, easy operation, economy and practicality, suitable for insitu detecting.

Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (MVA) vector booster vaccine encoding mosaic HIV antigens.

The invention relates to the immunization analysis medical field, and particularly provides a kit for determining the human immunodeficiency virus (HIV) antigen/antibody by the chemoluminescent immunization analysis and a preparation method thereof. The kit comprises (1) a solid carrier coated by the HIV antigens and antibodies; (2) biotin-labeled HIV antibodies; (3) enzyme-labeled HIV antigens and streptavidin; (4) a chemoluminescent primer acting with the above enzyme; and (5) a contrast. The preparation method of the kit includes the following steps of (1) coating the solid carrier with the HIV antigens and antibodies; (2) labeling the HIV antigens with a biotin; (3) labeling the HIV antigens and the streptavidin with the enzyme; (4) preparing the chemoluminescent primer, (5) preparing the contrast; (6) separately packaging; and (7) assembling into a finished product. The kit has the advantages of simpliness, rapidness, sensitiveness, stability and the like.

Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the immunogenic compositions to induce an immune response against an HIV in a subject. The immunogenic compositions can be administered alone, or in combination with one or more additional HIV antigens, or one or more adenovirus vectors encoding the one or more additional HIV antigens.

Microparticles with absorbed polypeptide-containing molecules formed without the use of surfactant, methods of making such microparticle compositions, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like. Preferred polymers are poly(D,L-lactide-co-glycolides), more preferable those having a lactide/glycolide molar ratio ranging from 40:60 to 60:40 and having a molecular weight ranging from 20,000 Daltons to 70,000 Daltons. Preferred polypeptide containing molecules are bacterial and viral antigens (including HIV antigens, meningitis B antigens, streptococcus B antigens, and Influenza A hemagglutinin antigens).

The invention discloses a double-labeling time-resolved fluorescence immunoassay method and kit for HIV (human immunodeficiency virus) antibody-HIV-1p24 antigen. The analytical method mainly comprises the steps of preparing a solid phase carrier coated with an HIV recombinant antigen and an HIV-1p24 monoclonal antibody simultaneously; preparing biotin-labeled HIV-1p24 monoclonal antibody; preparing lanthanide 1-labeled HIV recombinant antigen; preparing lanthanide 2-labeled streptavidin; adding a calibrator containing HIV standard antibody and HIV-1p24 standard antigen or a sample to be tested into the solid phase carrier coated with the antigen and the antibody, adding the biotin-labeled HIV-1p24 antibody, incubating, washing, then adding the lanthanide 1-labeled HIV antigen and the lanthanide 2-labeled streptavidin, incubating again, washing, and adding enhancement solution for fluorescence detection. The analytical method overcomes the difficulty that the antigen and the antibody cannot be distinguished in the existing joint detection for HIV antigen and antibody, realizes simultaneous and quantitative detection of the HIV antibody and the HIV-1p24 antigen and therefore shortens the window phase of HIV detection.

The present invention discloses development of a model live vaccine for HIV, using an attenuated strain of Salmonella engineered to surface express specific HIV proteins and testing of this vaccine in mice. There are provided two recombinant plasmids, containing the Lpp-OmpA genes required for surface exposure, followed by the genes for the HIV-1 proteins, Reverse Transcriptase or Transactivating protein (Tat). These plasmids are electroporated into an attenuated strain of Salmonella, and antigen expression is verified. These live vaccines are then used to orally inoculate mice and the vaccinated mice are tested for fecal IgA response and helper T cell response specific for the HIV antigens.

The invention belongs to the technical field of biological detection, and particularly relates to an HIV (human immunodeficiency virus) antigen antibody detection card and a preparation method thereof. The detection card comprises a card cover, a card body and a test strip, wherein the card cover is sequentially provided with a dilute solution adding hole, a sample adding hole, an observation hole and an installation marking hole; a groove for holding the test strip is arranged in the card body; and the test strip is sequentially provided with a sample pad layer, a colloidal gold layer, a nitrocellulose film and a water-absorbing layer. The preparation method comprises the following steps: preparing colloidal gold; respectively marking recombinant HIV-1/HIV-2 antigens and mouse anti-p24 monoclonal antibodies with the colloidal gold, marking p24 antibodies with biotin, immobilizing the colloidal gold and biotin markers, coating the nitrocellulose film, preparing the test strip, and buckling the detection card. The detection card provided by the invention can detect HIV antigen antibodies, and is high in sensitivity and low in sample consumption.

Modified HIV Env, Gag, Pol, or Nef DNA with improved ability to elicit antibody and CTL responses to HIV antigens have been identified as prototype immunogens for the treatment and prevention of HIV infections.

This invention discloses a multi-target quick test method for human immunodeficiency virus antibodies including: 1, expressing five kinds of HIV antigen white dribs and drabs-p24, gp41, gp36, gp120V3, gp120C in a colibacillus by a gene engineering technology, 2, fixing the five antigen whites on a pyroxylin film, 3, dripping armed serum on it and the virus antibody is combined with the antigen by a immunoreaction then adding the A(SPA) labeled by nm gold, 4, cleaning it after it penetrates the film, 5, adding SPA antibodies to increase the amplification to form red spots seen by eyes.

The present invention provides an improved method for eliciting a therapeutic immune response in an individual infected with human immunodeficiency virus (“HIV”). The method comprises administering an adenoviral vaccine composition expressing an HIV antigen to an individual with controlled viremia. Immunization of infected individuals in this manner elicits a cellular-mediated immune response against the virus that is significant both in the level of the response and the breadth of the response. The therapeutic immune response that ensues is capable of effectively maintaining low titers of virus and, thus, offers the prospect of reducing individual dependency on antiviral therapy.

The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compositions of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compositions of the invention can also be used to prevent and treat infection by HIV in humans.

Microparticles with adsorbed complexes of macromolecule and detergent, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surfaces of the microparticles have adsorbed thereon a complex of biologically active macromolecules, such as nucleic acids, polypeptides, antigens, and adjuvants, and a detergent. Preferred polymers are poly(D,L-lactide-co-glycolides), more preferably those having a lactide/glycolide molar ratio ranging from 40:60 to 60:40 and having a molecular weight ranging from 30,000 Daltons to 70,000 Daltons. Preferred macromolecules are bacterial and viral antigens (such as HIV antigens, meningitis B antigens, streptococcus B antigens, and Influenza A hemagglutinin antigens) as well as polynucleotides that encode for such antigens.

The invention provides a nucleotide sequence that encodes an HIV-1 gag protein or fragment thereof containing a gag epitope and a second HIV antigen or a fragment encoding an epitope of said second HIV antigen, operably linked to a heterologous promoter. Preferred polynucleotide sequences further encodes nef or a fragment thereof and RT or a fragment thereof.

The invention provides a method of inducing an immune response against a human immunodeficiency virus (HIV) in a mammal. The method comprises administering to the mammal an adenoviral vector composition comprising one or more adenoviral vectors encoding two or more different HIV antigens, the production of which induces an immune response against HIV in the mammal. The invention also provides an adenoviral vector composition comprising four adenoviral vectors encoding an HIV clade A Env protein, an HIV clade B Env protein, an HIV clade C Env protein, and a fusion protein comprising an HIV clade B Gag protein and Pol protein, respectively.

The invention provides a diagnostic kit for jointly detecting an HIV antigen and an HIV antibody. The HIV-1type p24 antigen and the HIV-1/2 type antibody are qualitatively detected by adopting the immunoadsorption test principle of a double antibody sandwich method and a double antigen sandwich method and combining a time-resolved fluorescence immunoassay technique; the window period of existing HIV detection can be shortened to be 2-3 weeks, and the diagnostic kit is beneficial for early diagnosis of an HIV and also can serve as a basis for prognostically judging and evaluating the antiviral therapy effect; meanwhile, the kit further has the advantages of being high in specificity and sensitivity, good in repeatability, excellent in stability, wide in measurable range, high in detection automation degree, free of environmental pollution and the like.